Tuoxin Pharmaceutical Group Co.,Ltd. (SHE:301089)

China · Delayed Price · Currency is CNY

29.24

-0.05 (-0.17%)

At close: Feb 27, 2026

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2023	FY 2022	FY 2020	FY 2020	FY 2019	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022	Dec '20 Dec 31, 2020	Jan '20 Jan 1, 2020	Jan '19 Jan 1, 2019	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Nucleotide Series	160.64M	146.23M	206.10M	250.61M	224.09M
Nucleotide Series Growth	9.85%	-29.05%	-17.76%	11.83%	-
Nucleoside Series	13.21M	463.76M	377.92M	99.57M	97.43M
Nucleoside Series Growth	-97.15%	22.71%	279.54%	2.20%	-
Pyrimidine Series	80.38M	48.03M	48.79M	80.17M	103.97M
Pyrimidine Series Growth	67.38%	-1.57%	-39.14%	-22.89%	-
Purine Series	133.86M	146.03M	124.64M	46.90M	72.72M
Purine Series Growth	-8.33%	17.16%	165.74%	-35.50%	-
Other	33.59M	31.46M	27.27M	25.22M	29.74M
Other Growth	6.78%	15.36%	8.10%	-15.18%	-
Total	421.69M	835.51M	784.72M	502.48M	527.94M
Total Growth	-49.53%	6.47%	56.17%	-4.82%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2023	FY 2022	FY 2020	FY 2020	FY 2019	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022	Dec '20 Dec 31, 2020	Jan '20 Jan 1, 2020	Jan '19 Jan 1, 2019	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
China	325.00M	751.94M	699.12M	343.72M	441.12M
China Growth	-56.78%	7.56%	103.40%	-22.08%	34.42%
Overseas	96.69M	83.57M	85.60M	158.77M	86.82M
Overseas Growth	15.71%	-2.38%	-46.08%	82.87%	53.61%
Total	421.69M	835.51M	784.72M	502.48M	527.94M
Total Growth	-49.53%	6.47%	56.17%	-4.82%	37.24%

Source: S&P Global Market Intelligence.